• UPDATE : 2018.8.19 일 15:34
상단여백
기사 (전체 60건)
Takeda Announces Phase 3 Trial of ALUNBRIG Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK
Takeda Pharmaceutical Company Limited (TSE: 4502) announced that the global...
라인
Phase 3 Trial of NINLARO as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the ...
라인
South Korea’s National Soccer Team Prepared 2018 Russia World Cup with Vaccination
Sanofi Pasteur in Korea(General Manager: Baptiste de Clarens) announced tha...
라인
라인
Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries
Family-owned pharmaceutical company Boehringer Ingelheim today presented it...
라인
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
Boehringer Ingelheim today announced an increase in funding for its corpora...
라인
AstraZeneca’s Calquence Shows Potential in Chronic Lymphocytic Leukaemia Trials
AstraZeneca and Acerta Pharma, its haematology research and development cen...
라인
라인
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases
(Business Wire/Korea Newswire) AstraZeneca today presented new data from a ...
라인
Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited [TSE: ...
라인
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential
(Business Wire/Korea Newswire) Boehringer Ingelheim today announced the lau...
라인
라인
Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited (TSE: ...
라인
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients
Janssen’s new once-daily, single tablet combination therapy SYMTUZA® (d...
라인
FASLODEX(FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB
AstraZeneca today announced that the Committee for Medicinal Products for H...
라인
라인
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’
IPF is a progressive and debilitating disease which causes continual and ir...
라인
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...
라인
AstraZeneca Presents Tagrisso(osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases
AstraZeneca today reported further evidence that Tagrisso (osimertinib), the potential new standard of care for adult pa...
라인
라인
ATS 2017 Spiriva Respimat improves breathing for people with asthma regardless of BMI or allergic status
Boehringer Ingelheim today announced new analyses that provide further evidence that adding tiotropium Respimat® (Sp...
라인
Takeda Reports FY2016 Full Year Results and Issues FY2017 Guidance
Takeda Pharmaceutical Company Limited (TOKYO:4502):Delivered substantial profit growth versus prior year· Underlying Rev...
라인
US FDA Expands Approval of Tiotropium Respimat for Maintenance Treatment of Asthma in Children
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved tiotropium Respimat® (mar...
라인
Takeda Recognized as One of the Global 100 Most Sustainable Corporations for Second Consecutive Year
Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights to the 2017 Glo...
라인
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (N...
-123-
Back to Top